This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.During concomitant use of Cataflam and lithium, monitor patients for signs of lithium toxicity.Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).During concomitant use of Cataflam and methotrexate, monitor patients for methotrexate toxicity.Concomitant use of Cataflam and cyclosporine may increase cyclosporine’s nephrotoxicity.During concomitant use of Cataflam and cyclosporine, monitor patients for signs of worsening renal function.Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended.Concomitant use of Cataflam and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).During concomitant use of Cataflam and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9. Yes, cataflam is effective in treatment of acute pain, mild to moderate. Version: 17.02.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.During concomitant use of Cataflam with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.During concomitant use of Cataflam and digoxin, monitor serum digoxin levels.NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. Ponstan is better.
For more information, ask your healthcare provider or pharmacist about NSAIDs.Call your doctor for medical advice about side effects. Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. Cataflam is available as immediate-release tablets of 50 mg (light brown) for oral administration. rifampin) may lead to compromised efficacy of diclofenac.A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers Long-term carcinogenicity studies in rats given diclofenac sodium up to 2 mg/kg/day (approximately 0.1 times the maximum recommended human dose (MRHD) of Cataflam, 200 mg/day, based on body surface area (BSA) comparison) have revealed no significant increase in tumor incidence. They may contain ingredients similar to diclofenac (such as aspirin, Stop using Cataflam and call your doctor at once if you have:the first sign of any skin rash, no matter how mild;This is not a complete list of side effects and others may occur. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg three times a day. Do not use NSAIDs for a condition for which it was not prescribed. Cataflam 50 mg was prescribed in combination with Amoxil 500 mg (one tablet 3 - Answered by a verified Doctor We use cookies to give you the best possible experience on our website.

Meaningful elevations of ALT and/or AST occurred in about 4% of patients and included marked elevations (greater than 8 times the ULN) in about 1% of the 3,700 patients.